Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
NCT02254031 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8
Last updated 2023-10-24
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Conditions
- Breast Neoplasms
Interventions
- DRUG
-
bivatuzumab mertansine
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-07-01
- Primary Completion
- 2005-01-01
More Related Trials
-
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
NCT03842085 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
NCT00773344 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
NCT00717405 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
NCT03307785 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
NCT02952729 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
NCT00788333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
NCT04111458 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT03393845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03379428 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
NCT03023319 ·Status: COMPLETED ·Phase: PHASE1
-
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
NCT06361979 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
NCT00412412 ·Status: COMPLETED ·Phase: PHASE1
-
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932 ·Status: RECRUITING ·Phase: PHASE1
-
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
NCT00759837 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
NCT00454532 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)
NCT02259114 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
NCT03065010 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06445400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
NCT02854618 ·Status: UNKNOWN ·Phase: NA
-
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT03566485 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line
NCT03462251 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
NCT02386501 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
NCT06298084 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776 ·Status: RECRUITING